acquired
Stage
About
Ambrx Biopharma is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates and engineered protein therapies using an expanded genetic code platform for oncology and immune modulation. It has advanced clinical programs including ARX517 and ARX788 and was acquired by Johnson & Johnson in March 2024.
Explore Ambrx Biopharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.